S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:KPTI

Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

$5.07
-0.16 (-3.06%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.98
$5.29
50-Day Range
$4.43
$5.93
52-Week Range
$4.00
$14.73
Volume
2.01 million shs
Average Volume
2.52 million shs
Market Capitalization
$411.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.13

Karyopharm Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
99.7% Upside
$10.13 Price Target
Short Interest
Bearish
19.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.10mentions of Karyopharm Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$72,571 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.95) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

445th out of 1,023 stocks

Pharmaceutical Preparations Industry

198th out of 501 stocks

KPTI stock logo

About Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

Karyopharm Announces $165 Million Private Placement
Karyopharm Therapeutics Inc. (KPTI)
Expert Ratings for Karyopharm Therapeutics
Karyopharm to Participate at Upcoming Investor Conferences
Why Karyopharm Therapeutics Inched Higher Today
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Company Calendar

Last Earnings
11/03/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/14/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
442
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.13
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+99.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-124,090,000.00
Pretax Margin
-35.19%

Debt

Sales & Book Value

Annual Sales
$209.82 million
Book Value
($1.05) per share

Miscellaneous

Free Float
72,845,000
Market Cap
$411.46 million
Optionable
Optionable
Beta
-0.11

Key Executives

  • Mr. Richard A. Paulson M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $1.27M
  • Dr. Sharon Shacham M.B.A. (Age 52)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
    Comp: $766.54k
  • Mr. Michael P. Mason CPAMr. Michael P. Mason CPA (Age 47)
    M.B.A., Exec. VP, CFO & Treasurer
    Comp: $692.39k
  • Mr. Ran Frenkel R.Ph. (Age 53)
    RPh, Global Head of Clinical Operations
    Comp: $667.87k
  • Dr. Mansoor Raza Mirza M.D. (Age 61)
    Clinical Consultant, Member of Scientific Advisory Board & Independent Director
    Comp: $146.14k
  • Mr. Cameron Peters (Age 62)
    VP of Fin., Assistant Treasurer & Principal Accounting Officer
  • Mr. Pierre S. Sayad M.S.
    Ph.D., VP of Global Medical & Scientific Affairs
  • Ms. Elhan Webb C.F.A.
    Sr. VP of Investor Relations
  • Mr. Michael J. Mano J.D. (Age 45)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. James Accumanno J.D.
    Chief Compliance Officer













KPTI Stock - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KPTI shares.
View KPTI analyst ratings
or view top-rated stocks.

What is Karyopharm Therapeutics' stock price forecast for 2023?

7 Wall Street research analysts have issued 1-year price targets for Karyopharm Therapeutics' stock. Their KPTI share price forecasts range from $6.00 to $18.00. On average, they predict the company's stock price to reach $10.13 in the next twelve months. This suggests a possible upside of 98.1% from the stock's current price.
View analysts price targets for KPTI
or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2022?

Karyopharm Therapeutics' stock was trading at $6.43 at the beginning of 2022. Since then, KPTI shares have decreased by 20.5% and is now trading at $5.11.
View the best growth stocks for 2022 here
.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our KPTI earnings forecast
.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its earnings results on Wednesday, November, 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.01. The firm earned $37.69 million during the quarter, compared to analyst estimates of $25.84 million. During the same period in the previous year, the company earned ($0.73) earnings per share.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155.00 million-$165.00 million, compared to the consensus revenue estimate of $157.23 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (11.10%), BlackRock Inc. (9.75%), Vanguard Group Inc. (5.93%), Rubric Capital Management LP (4.92%), Nuveen Asset Management LLC (2.43%) and Jacobs Levy Equity Management Inc. (1.95%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends
.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $5.11.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $414.68 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

The company employs 442 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.

This page (NASDAQ:KPTI) was last updated on 12/6/2022 by MarketBeat.com Staff